Rachel A Gibson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3035960/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of topical applications of sunflower seed oil on systemic fatty acid levels in under-two children under rehabilitation for severe acute malnutrition in Bangladesh: a randomized controlled trial. Nutrition Journal, 2021, 20, 51.	3.4	4
2	Topical emollient therapy with sunflower seed oil alters the skin microbiota of young children with severe acute malnutrition in Bangladesh: A randomised, controlled study. Journal of Global Health, 2021, 11, 04047.	2.7	4
3	Topical emollient therapy in the management of severe acute malnutrition in children under two: A randomized controlled clinical trial in Bangladesh. Journal of Global Health, 2020, 10, 010414.	2.7	7
4	Intakes and Food Sources of Dietary Fibre and Their Associations with Measures of Body Composition and Inflammation in UK Adults: Cross-Sectional Analysis of the Airwave Health Monitoring Study. Nutrients, 2019, 11, 1839.	4.1	21
5	Nutrient profiling and adherence to components of the UK national dietary guidelines association with metabolic risk factors for CVD and diabetes: Airwave Health Monitoring Study. British Journal of Nutrition, 2018, 119, 695-705.	2.3	15
6	A randomized, doubleâ€blind, placebo ontrolled trial of camicinal in Parkinson's disease. Movement Disorders, 2018, 33, 329-332.	3.9	14
7	A cross-sectional investigation into the occupational and socio-demographic characteristics of British police force employees reporting a dietary pattern associated with cardiometabolic risk: findings from the Airwave Health Monitoring Study. European Journal of Nutrition, 2018, 57, 2913-2926.	3.9	24
8	Objective assessment of dietary patterns by use of metabolic phenotyping: a randomised, controlled, crossover trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 184-195.	11.4	194
9	Dietary assessment of British police force employees: a description of diet record coding procedures and cross-sectional evaluation of dietary energy intake reporting (The Airwave Health Monitoring) Tj ETQq1 1 0.7	78 43 914 rgi	BT 20 verlock
10	A Randomised Trial Evaluating the Effects of the TRPV1 Antagonist SB705498 on Pruritus Induced by Histamine, and Cowhage Challenge in Healthy Volunteers. PLoS ONE, 2014, 9, e100610.	2.5	57
11	DNAJC13 mutations in Parkinson disease. Human Molecular Genetics, 2014, 23, 1794-1801.	2.9	258
12	Populationâ€specific frequencies for <i>LRRK2</i> susceptibility variants in the genetic epidemiology of Parkinson's disease (GEOâ€PD) consortium. Movement Disorders, 2013, 28, 1740-1744.	3.9	30
13	Genetic variation in GOLM1 and prefrontal cortical volume in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 457-465.	3.1	14
14	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study. Lancet Neurology, The, 2011, 10, 898-908.	10.2	294
15	Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease. American Journal of Human Genetics, 2011, 89, 398-406.	6.2	250
16	Rare Deletions at 16p13.11 Predispose to a Diverse Spectrum of Sporadic Epilepsy Syndromes. American Journal of Human Genetics, 2010, 86, 707-718.	6.2	231
17	Heterodimerization of Lrrk1–Lrrk2: Implications for LRRK2-associated Parkinson disease. Mechanisms of Ageing and Development, 2010, 131, 210-214.	4.6	18
18	Comprehensive sequencing of the <i>LRRK2</i> gene in patients with familial Parkinson's disease from North Africa. Movement Disorders, 2010, 25, 2052-2058.	3.9	23

RACHEL A GIBSON

#	Article	IF	CITATIONS
19	An exploration of cognitive subgroups in Alzheimer's disease. Journal of the International Neuropsychological Society, 2010, 16, 233-243.	1.8	35
20	Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain, 2010, 133, 2136-2147.	7.6	132
21	Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. Neuroscience Letters, 2010, 477, 57-60.	2.1	30
22	A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 391-395.	1.9	44
23	Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Human Molecular Genetics, 2009, 18, 2078-2090.	2.9	371
24	<i>ATP13A2</i> variability in Parkinson disease. Human Mutation, 2009, 30, 406-410.	2.5	37
25	Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics, 2009, 41, 776-782.	21.4	729
26	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics, 2009, 18, 767-778.	2.9	419
27	Anatomically-distinct genetic associations of APOE É>4 allele load with regional cortical atrophy in Alzheimer's disease. NeuroImage, 2009, 44, 724-728.	4.2	144
28	Proteomic identification and early validation of complement 1 inhibitor and pigment epitheliumâ€derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics - Clinical Applications, 2008, 2, 467-477.	1.6	52
29	An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases. European Journal of Human Genetics, 2008, 16, 176-183.	2.8	5
30	LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study. Lancet Neurology, The, 2008, 7, 591-594.	10.2	172
31	The ancestry of LRRK2 Gly2019Ser parkinsonism – Authors' reply. Lancet Neurology, The, 2008, 7, 770-771.	10.2	5
32	Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease. Archives of Neurology, 2008, 65, 45-53.	4.5	443
33	Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Movement Disorders, 2007, 22, 55-61.	3.9	100
34	Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurology, The, 2007, 6, 970-980.	10.2	175
35	Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 2 G2019S Mutations. Archives of Neurology, 2006, 63, 1250.	4.5	91
36	Age at Onset in Two Common Neurodegenerative Diseases Is Genetically Controlled. American Journal of Human Genetics, 2002, 70, 985-993.	6.2	291

RACHEL A GIBSON

#	Article	IF	CITATIONS
37	Complete Genomic Screen in Parkinson Disease. JAMA - Journal of the American Medical Association, 2001, 286, 2239.	7.4	257
38	Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism. Nature Genetics, 1999, 22, 379-383.	21.4	190
39	Exon 6 skipping in the fanconi anemia C gene associated with a nonsense/missense mutation (775C→T) in exon 5: The first example of a nonsense mutation in one exon causing skipping of another downstream. Human Mutation, 1998, 11, S25-S27.	2.5	6
40	Construction of a High-Resolution Physical and Transcription Map of Chromosome 16q24.3: A Region of Frequent Loss of Heterozygosity in Sporadic Breast Cancer. Genomics, 1998, 50, 1-8.	2.9	28
41	The Genomic Organization of the Fanconi Anemia Group A (FAA) Gene. Genomics, 1997, 41, 309-314.	2.9	51
42	VACTERL with hydrocephalus in twins due to Fanconi anemia (FA): Mutation in the FAC gene. American Journal of Medical Genetics Part A, 1997, 68, 86-90.	2.4	39
43	Novel mutations and polymorphisms in the Fanconi anemia group C gene. Human Mutation, 1996, 8, 140-148.	2.5	42
44	Positional cloning of the Fanconi anaemia group A gene. Nature Genetics, 1996, 14, 324-328.	21.4	294
45	Localisation of the Fanconi anaemia complementation group A gene to chromosome 16q24.3. Nature Genetics, 1995, 11, 338-340.	21.4	89
46	A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. Nature Genetics, 1993, 4, 202-205.	21.4	161
47	A nonsense mutation and exon skipping in the Fanconi anaemia group C gene. Human Molecular Genetics, 1993, 2, 797-799.	2.9	87
48	EcoRI RFLP in the Fanconi anaemia complementation group C gene (FACC). Human Molecular Genetics, 1993, 2, 1509-1509.	2.9	2
49	Characterisation of the exon structure of the Fanconi anaemia group C gene by vectorette PCR. Human Molecular Genetics, 1993, 2, 35-38.	2.9	49
50	Pharmacokinetics and Safety of Inhaled Oxytocin Compared with Intramuscular Oxytocin: The First Randomised Open-Label Study in Women in the Third Stage of Labour. SSRN Electronic Journal, 0, , .	0.4	0